News Releases

Month Year

Aug 24, 2016

RegeneRx Joint Venture to Begin Second Phase 3 Study Of RGN-259 for Dry Eye Syndrome in 3rd Quarter

FDA Accepts Phase 3 Design Based on Results from Previous Phase 2b/3 Dry Eye Trial

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Aug 3, 2016

RegeneRx Receives Notice of Allowance for Key U.S. Patent That Expands and Extends Exclusivity of Company's Product Candidates

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 27, 2016

RegeneRx Announces $1.75 Million Private Placement

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that...
Jun 14, 2016

Thymosin Beta 4 Effective in Treatment of Heart Attack Patients

First Human Study Demonstrates Significant Clinical and Functional Improvements

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced a...
Jun 1, 2016

RegeneRx and Lee's Pharm Announce Acceleration of RGN-259 Development in China

RegeneRx Biopharmaceuticals, Inc. ("RegeneRx", OTCQB: RGRX), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee's Pharmaceutical Holdings...

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa